Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.
증례보고
1/5 보강
Prostate cancer with bone marrow carcinomatosis is rare and has a poor prognosis.
APA
Nagaya N, Hokota K, et al. (2025). Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.. Urology case reports, 63, 103245. https://doi.org/10.1016/j.eucr.2025.103245
MLA
Nagaya N, et al.. "Multidisciplinary therapy targeting histological heterogeneity in prostate cancer with bone marrow carcinomatosis: A case report.." Urology case reports, vol. 63, 2025, pp. 103245.
PMID
41142191 ↗
Abstract 한글 요약
Prostate cancer with bone marrow carcinomatosis is rare and has a poor prognosis. A 68-year-old man with severe thrombocytopenia was diagnosed with prostate cancer based on MRI and bone marrow biopsy findings. Initial treatment with a GnRH antagonist and apalutamide showed limited efficacy for thrombocytopenia despite PSA response, prompting the addition of carboplatin and etoposide (CE) chemotherapy. Thrombocytopenia resolved following CE chemotherapy. After four CE cycles, ProGRP stabilized and PSA decreased significantly. Tumor control was maintained for a year with hormonal therapy. This case underscores the need for early, multidisciplinary treatment in histologically heterogeneous prostate cancer.